Cabot (CBT) Stock: Buy, Sell, or Hold?
CBT - Cabot Corporation
$76.95
0.60 (0.79%)
▲
5d:
-2.3%
30d:
-7.11%
90d:
-12.16%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 02, 2026
29d
Get Alerted When CBT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CBT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CBT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$109.14
Based on 6.9% avg growth
INTRINSIC VALUE TODAY
$67.77
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CBT is currently trading at $76.95, which is considered oversold relative to its 30-day fair value range of $77.51 to $82.46. The stock's valuation (Forward PE: 11.0) is in line with its historical norms (11.2). Remarkably, the market is currently pricing in an annual earnings decline of 0.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CBT is in a downtrend. Immediate support is located at $74.55, while resistance sits at $80.11.
Market Sentiment: CBT scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $91.33 (+18.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CBT is in a downtrend. Immediate support is located at $74.55, while resistance sits at $80.11.
Market Sentiment: CBT scores 69/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $91.33 (+18.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$77.51 -
$82.46
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (69/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($91.33)
- CAUTION: Bottoming setup, but lagging the sector by 19% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$77.51 -
$82.46
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$74.55
Resistance Level
$80.11
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.01
Wall Street Target
$91.33
(+18.7%)
Revenue Growth (YoY)
6.4%
Earnings Growth (YoY)
-93.7%
Profit Margin
5.2%
Valuation Discount vs History
-0.4% cheaper
PE vs Historical
11.0 vs 11.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.4%
(market-implied from PE analysis)
1-Year Target
$76.64
(0%)
2-Year Target
$76.34
(-1%)
3-Year Target
$76.03
(-1%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
$77.32
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 9.8%)
$188.92
(+146%)
Base:
(SPY PE: 11.0, Growth: 9.8%)
$101.99
(+33%)
Bear:
(PE: 9.4, Growth: 9.8%)
$86.69
(+13%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 21.57 | Current EPS (TTM): $3.54
Bull Case
$165.76
(+115%)
Analyst growth 97.4%, PE expands to 23.7
Base Case
$150.69
(+96%)
Market implied 97.4%, PE stable at 21.6
Bear Case
$51.92
(-33%)
Severe decline -20.0%, PE contracts to 18.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.0 to 11.2
Stabilization Target:
$78.25
(+1.7%)
PE Expansion Potential:
+1.7%
Share & Embed Analysis
Last updated: October 02, 2026 9:40 PM ET
Data refreshes hourly during market hours. Next update: 10:40 PM
Data refreshes hourly during market hours. Next update: 10:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CBT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Specialty Chemicals Stocks
Top-rated stocks in Specialty Chemicals by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ECL
Ecolab Inc |
STRONG BUY
27 analysts |
$325 | 51 HOLD |
|
LIN
Linde plc Ordinary Shares |
BUY
28 analysts |
$543 | 48 HOLD |
|
SHW
Sherwin-Williams Co |
BUY
28 analysts |
$389 | 51 HOLD |
|
APD
Air Products and Chemica… |
BUY
24 analysts |
$345 | 58 HOLD |
|
ALB
Albemarle Corp |
HOLD
28 analysts |
$172 | 56 HOLD |
